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Gilbert’s syndrome and hereditary hemochromatosis predominantly affect Caucasians with a low incidence in Asians.
Here we report the case of a 16-year-old Chinese boy, who was admitted with hepatalgia, jaundice, hyperpigmentation,
and splenomegaly to our hospital. After excluding chronic hepatitis, autoimmune disorders, and alcohol or drug injury,
genetic analyses of the patient and his parents revealed simultaneous manifestations of Gilbert’s syndrome and
hereditary hemochromatosis, though his parents did not develop related symptoms. The presented case indicates
that diagnoses of Gilbert’s syndrome and hereditary hemochromatosis should be taken into consideration when
chronic hepatitis is suspected without a clear etiology.
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Hereditary hemochromatosis (HHC) is an autosomal re-
cessive genetic disorder caused by mutations in the high
iron Fe (HFE) gene, which leads to exacerbated iron uptake
and storage [1]. Gilbert’s syndrome (GS) is an autosomal
inherited disease that manifests as intermittent unconju-
gated hyperbilirubinemia. It is caused by mutations of the
UDP-glucuronosyltransferase1A1 (UGT1A1) gene, which
has the function of rendering bilirubin water soluble via
glucuronidation [2]. Because of the low HHC prevalence in
Asians [3,4] and the high rate of GS unawareness [5],
adolescent HHC concurrent with GS cases are rarely found
in China.
Case presentation
A 16-year-old boy was admitted to our hospital with a
1-year history of repeated epigastric pain and 6 months
mild jaundice. We found skin hyperpigmentation, liver
tenderness, splenomegaly, and mild jaundice of the skin
and sclera during physical examination, while the first
onset of skin hyperpigmentation occurred 3 years ago.* Correspondence: Wangxianbo022714@163.com; chinaroc@tom.com
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unless otherwise stated.We first presumed that he might have developed chronic
hepatitis, caused by virus infections, drug or alcohol
abuse, or autoimmune/metabolic disorders. Laboratory
tests revealed 61.8 μmol/L total bilirubin (TBIL) (normal
range, 0 to 18.8 μmol/L) and 7.5 μmol/L direct bilirubin
(DBIL) (normal range, 0 to 6.8 μmol/L) concentrations,
pointing to Gilbert’s syndrome. Iron metabolism ana-
lyses indicated abnormal serum concentrations of iron
(39.42 μmol/L; normal range, 9.5 to 29.9 μmol/L), ferritin
(410.02 ng/mL; normal range, 21.81 to 274.66 ng/mL) and
transferrin (187.00 mg/dl; normal range, 200 to 400 mg/dl)
(Table 1). Other serological parameters were normal
(Table 1). An abdominal ultrasound examination re-
vealed diffused liver lesions and splenomegaly (28 mm
below the costal margin) but no abnormalities in the
extrahepatic bile ducts or pancreas. Negative hepatitis
serology, autoimmune antibody, and copper-protein re-
sults meant that viral hepatitis, autoimmune hepatitis, and
Wilson’s disease could be excluded from the diagnosis. Be-
cause the patient did not consume alcohol or take drugs,
did not receive blood transfusions or iron-supplementary
nutrition, or ingest hepatotoxic drugs or chalybeate
(natural mineral springs containing iron salts), we could
also exclude secondary hemochromatosis, alcoholic hepa-
titis, and drug-induced hepatitis. In order to clarify the
cause of the liver injury, a liver biopsy was carried out andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The baseline characteristics of the patient
Laboratory parameters Results Normal range
Iron (μmol/L) 39.42 9.5-29.9
Transferrin (mg/dL) 187 200-400
Ferritin (ng/mL) 410.02 21.81-274.66
Alanine aminotransferase (ALT) (U/L) 8.4 9.00-50.00
Aspartate aminotransferase (AST) (U/L) 15.1 15.00-40.00
Total bilirubin (TBIL) (μmol/L) 61.8 0-18.80
Direct bilirubin (DBIL) (μmol/L) 7.5 0-6.80
Total protein (TP) (g/L) 76.9 65.00-85.00
Albumen (ALB) (g/L) 49.4 40.00-55.00




Alkaline phosphatase (ALP) (U/L) 110.3 45.00-125.00
Cholinesterase (CHE) (U/L) 6882 4000.00-11000.00
Total bile acid (TBA) (μmol/L) 3.6 0-10.00
Prothrombin activity (PTA) (%) 68.3 80-120
White blood cell (WBC) (109/L) 8.79 4.00-10.00
Neutrophilic (%) 62.5 50.00-75.00
Lymphocytes (%) 31.2 20.00-40.00
Red blood cell (RBC) (1012/L) 3.71 4.00-5.50
Hemoglobin (HB) (g/L) 133.4 120.00-160.00
Platelet (PLT) (109/L) 290 100.00-300.00
Anti-nuclear antibody (ANA) Negative Negative
Anti-mitochondria antibody (AMA) Negative Negative
Anti-smooth muscle antibody (SMA) Negative Negative
Human anti-gastric parietal cell
antibody (AGPA)
Negative Negative







Human anti-centromere antibody (ACA) Negative Negative
Immunoglobulin G (g/L) 12.7 7.51-15.60
Immunoglobulin A (g/L) 2.02 0.82-4.53
Immunoglobulin M (g/L) 1.49 0.40-2.74
Complement 3 (C3) (g/L) 0.53 0.79-1.52
Complement 4 (C4 ) (g/L) 0.13 0.16-0.38
Ceruloplasmin (g/L) 0.21 0.22-0.58
Rheumatoid factor (RF) (IU/mL) <20 0-20.00
α1-Globulin (g/L) 3.6 2.9-4.9
α2-Globulin (g/L) 5.3 7.1-11.8
β1-Globulin (g/L) 4.3 4.7-7.2
β2-Globulin (g/L) 2.9 3.2-6.5
γ-Globulin (g/L) 16.6 11.1-18.8
Table 1 The baseline characteristics of the patient
(Continued)
Hepatitis B surface antigens
(HBsAg) (IU/mL)
Negative <0.05
Anti-HCV (S/CO) 0.11 <1
Blood glucose (μmol/L) 5.09 4.16-6.44
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cytes in zone 1 of the hepatic acinus (Figure 1A,B) as well
as excessive iron in acinar zone 3 hepatocytes around the
central vein (Figure 1C,D). The histopathological findings
made us take a diagnosis of hereditary hemochromatosis
(HHC) into consideration, though his family did not have
a history of obvious HHC or disorders of iron metabolism.
Gene analysis (SeqMan DNA Star 6.0 software, Lasergene,
Madison, WI, USA) after amplifications with specific
primers (Applied Biosystems, Carlsbad, CA, USA) revealed
a heterozygous H63D and a homozygous IVS 2 + 4 T→C
mutation in HFE as well as a heterozygous G71R mutation
in the UGT1A1 gene, confirming the diagnosis of HFE-
related HHC and concurrent GS. After the definite diagno-
sis, the patient was discharged and a 300 mL therapeutic
phlebotomy performed each week. However, after 9 weeks,
the TBIL, iron, and ferritin serum levels of the patient were
slightly enhanced (Table 2). We adjusted the bloodletting
protocol to 400 mL per week and urged the patient to
attend the clinic for phlebotomies more regularly. After
9 weeks, the relevant serum concentrations were de-
creased significantly and 4 weeks later, the TBIL and
iron levels were reduced further (Table 2), with the
patient’s symptoms being obviously relieved.
The research was approved by the ethics committee of
Beijing Ditan hospital, Capital Medical University.
Discussion
The low prevalence in China and non-specific symp-
toms can mean that the diagnosis of HHC might some-
times be overlooked. However, as the patient developed
hyperferritinemia, we suspected hemochromatosis and
since he had not previously had blood transfusions or
ingested chalybeate, secondary hemochromatosis could
be excluded. However, for a definite HHC diagnosis, gen-
etic testing is necessary and we also genetically screened
the patient’s first-degree relatives. His mother was found
to be a homozygous IVS 2 + 4 T→C and heterozygous
UGT1A1 G71R mutation carrier without symptoms. His
father was homozygous for IVS 2 + 4 T→C and has a
heterozygous H63D mutation. His UGT1A1 gene contains
a heterozygous G71R and an additional heterozygous
Y486D mutation, which he did not pass over to his son.
Some authors suggest that IVS 2 + 4 T→C might be
involved in specific splice activity [6] but no correlation
with HHC or the incidence of iron overload could be
Figure 1 Hepatic biopsy tissues (A and B: hematoxylin-eosin staining showing lipofuscin sedimentation (arrows) in acinar zone 1
hepatocytes. C and D: prussian blue staining showing iron deposits (arrows) in the peripheral hepatic cells of the central vein.
Original magnification: A and C ×200; B and D, ×400).
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toms in the patient’s mother. In contrast to Caucasians,
HHC is rare in Asians and mostly restricted to H63D mu-
tations in the HFE gene [9,10]. A H63D heterozygous mu-
tation is not generally associated with a hemochromatosis
phenotype unless it occurs as a C282Y-H63D compound
heterozygosity, or additional exogenous factors are trig-
gered. Although symptoms of obvious iron overload were
absent in the father, his serum iron concentration of
33.44 μmol/L was slightly elevated and the 198 mg/dL
transferrin value was close to the lower limit of the
normal range.
G71R is the most common single nucleotide poly-
morphism (SNP) of the UGT1A1 gene in Asia. Hepatic
glucuronidation activity in subjects with heterozygous
G71R mutations were 60.2 ± 3.5% of the wild type
activity, which was considered somewhat high for a sub-
ject to develop GS [9] and is in accordance with the nor-
mal bilirubin serum concentration of the patient’s mother.Table 2 Changes of ferrokinetic parameters and bilirubin leve
Follow-up Bloodletting therapy TBIL (μmol/L) DBIL (μmol/L)
0 0 61.80 7.50
1 300 mL/week 105.60 9.80
2 400 mL/week 41.70 7.40
3 400 mL/week 37.20 7.60In contrast, Y486D SNP were reported to have stronger
inhibitory effects on UGT1A1 and most Asian GS patients
belong to the compound G71R/Y486D mutation group
[10,11]. The data of the patient’s father are in line with
these findings because his UGT1A1 gene contains hetero-
zygous G71R plus Y486D mutations with resulting en-
hanced bilirubin levels. Extraordinarily, our 16-year-old
patient, who has only one heterozygous UGT1A1 SNP
(G71R), developed even higher TBIL and DBIL serum
concentrations (Table 3).
HFE mutations alone do not automatically produce
symptoms of iron overload. Iron stores and inflammation
are inducers of hepcidin, which acts as negative regulator
of iron absorption in the small intestine as well as iron
release from macrophages [12]. Impairment of hepcidin
activity, which is principal regulator of systemic iron
homeostasis, has been correlated with HFE-related
hemochromatosis [13]. Also, bilirubin levels are thought to
influence the state of iron homeostasis. An earlier publicationls in the patient’s serum during bloodletting therapy





Table 3 Bilirubin levels and ferrokinetic parameters in the family
TBIL (μmol/L) DBIL (μmol/L) IBIL (μmol/L) Serum iron (μmol/L) Transferrin (mg/dL) Ferritin (ng/mL)
The patient 61.80 7.50 54.30 39.42 187.00 410.02
His father 27.20 9.40 17.80 33.44 198.00 44.78
His mother 14.80 3.00 11.80 13.27 246.42 91.80
Normal ranges: TBIL, 0-18.8 μmol/L; DBIL, 0-6.8 μmol/L; serum iron, 9.5-29.9 μmol/L; transferrin, 200-400 mg/dL; ferritin, 21.81-274.66 ng/mL.
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http://www.eurjmedres.com/content/19/1/51noted that 23% of HHC patients showed increased un-
conjugated bilirubin serum concentrations [14]. Bilirubin
is an antioxidant [15] and iron causes oxidative stress [16];
oxidative stress-induced hemeoxygenase-1 activity has
been proposed to cause enhanced bilirubin serum con-
centrations in some HFE mutation carriers, which coun-
teracts the high oxidative stress produced by excess iron
and may thus contribute to reduced penetrance [17]. The
protective role of bilirubin in individuals with HFE muta-
tions might be applicable to the patient’s father, but based
on observations of patients with HHC and simultaneous
mutations of the UGT1A1 gene, Romanowski et al. pro-
posed that high levels of bilirubin might promote iron
loading by decreasing oxidative stress, in addition to re-
duced hepcidin signaling due to less inflammatory pro-
cesses [18], which might explain the iron overload in
the son. Notably, the son developed more pronounced
enhancements of TBIL and IBIL serum concentrations
compared to his father, even though he has one less
mutation in his UGT1A1 gene. We suggest that in this
case, increased iron absorption lead to oxidative stress
and induced heme oxygenase, resulting in an increase
in serum bilirubin. The higher bilirubin levels led to
higher iron storage tolerance and in turn triggered even
more heme oxygenase activity. Finally, the balance
between oxidative stress and antioxidant bilirubin pro-
duction caused the pronounced elevated bilirubin and
serum iron concentrations.Conclusions
In summary, our 16-year-old Chinese patient with
hepatalgia, jaundice, hyperpigmentation, and splenomegaly
was shown to be a heterozygous H63D and homozygous
IVS 2 + 4 T→C HFE and heterozygous G71R UGT1A1
gene mutation patient with simultaneous HHC and GS
manifestations. Astonishingly his father, who had the same
SNPs in both genes plus an additional heterozygous Y486D
mutation in UGT1A1, was not affected.Consent
Written informed consent was obtained from the patient’s
parents for the publication of this report and any accom-
panying images.Abbreviations
DBIL: Direct bilirubin; GS: Gilbert’s syndrome; HHC: Hereditary
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